Persaud Andrea, Lebwohl Mark
Department of Dermatology, The Mount Sinai School of Medicine of New York University, New York, NY 1029, USA.
J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S236-9. doi: 10.1067/mjd.2002.126581.
We studied the usefulness of imiquimod cream in the treatment of 3 patients with actinic keratoses. One patient was treated 3 times per week for 4 weeks and had a marked inflammatory response with nearly complete resolution of actinic keratoses. Two subsequent patients were treated in a bilateral paired comparison study. Both patients had similar numbers of actinic keratoses on symmetric areas and treated only one side with imiquimod cream 2 to 3 times per week with frequent rest periods to avoid inflammation. Both experienced marked reductions in actinic keratoses. After 8 weeks, both patients applied imiquimod cream twice per week for 9 months with continued reduction in actinic keratoses on both sides. Treatments were well tolerated. Imiquimod cream appears to be effective in the treatment of actinic keratoses. The main adverse effect is local inflammation, which can be avoided by reducing the frequency of application.
我们研究了咪喹莫特乳膏治疗3例光化性角化病患者的有效性。1例患者每周治疗3次,共治疗4周,出现明显的炎症反应,光化性角化病几乎完全消退。随后在一项双侧配对对照研究中对另外2例患者进行了治疗。这2例患者对称部位的光化性角化病数量相似,仅对一侧每周使用2至3次咪喹莫特乳膏进行治疗,并经常休息以避免炎症。二者的光化性角化病均显著减少。8周后,这2例患者每周使用2次咪喹莫特乳膏,持续9个月,双侧光化性角化病持续减少。治疗耐受性良好。咪喹莫特乳膏似乎对光化性角化病有效。主要不良反应是局部炎症,可通过减少用药频率来避免。